AP

Andrew Wong, PhD

Head of Automation and Engineering at Inscripta, Inc.

Andrew Wong, PhD is currently the Head of Automation and Engineering at Inscripta, Inc. Andrew joined the company in January 2023. Prior to that, from June 2022 to January 2023, they held the same position at Infinome Biosciences. Before that, from July 2021 to May 2022, they worked as a Staff Systems Engineer at Inscripta, Inc. and from June 2018 to July 2021, they served as a Sr. Systems Engineer II at the same company. From March 2018 to June 2018, they were the Manager Software Engineering at Roche Sequencing Solutions. From February 2015 to February 2018, they were the Systems Engineering Manager at Roche Sequencing Solutions (formerly Ariosa Diagnostics). From August 2012 to January 2015, they worked as a Sr. Systems Engineer at Ariosa Diagnostics. From September 2010 to August 2012, they served as a Field Automation Engineer at Tecan. From September 2002 to September 2009, they were a Graduate Student Researcher at UC Davis. Andrew also had an internship at Aqua Bounty Technologies in October 2007. Their career began as a Research Assistant at Applied Biosystems, where they worked from September 1997 to September 2002.

Andrew Wong, PhD, has a strong educational background, particularly in the field of genetics. Starting in 1999, they attended the University of California, Berkeley, where they obtained a Bachelor of Arts (BA) degree in Molecular and Cellular Biology in 2001. Following this, they pursued further studies at the same institution and earned a second BA degree in Integrative Biology in 2002. Andrew's educational journey continued at the University of California, Davis, where they completed their doctoral studies. From 2002 to 2009, they focused on Genetics and ultimately received a PhD.

Location

San Francisco, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Inscripta, Inc.

Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale.


Employees

51-200

Links